Allcyte

About:

Allcyte is a biotech start-up focused on precision medicine and drug development in a patient-centric way using high-content imaging and AI

Website: https://www.allcyte.com/

Twitter/X: allcyte

Top Investors: PUSH VC, EIT Health, 42CAP, Air Street Capital, Amino Collective

Description:

Allcyte is a biotech start-up company focused on functional drug testing in primary human material. With our Pharmacoscopy high-content imaging platform and AI-supported image analysis pipelines, our mission is to bring the next generation of personalized medicine to cancer patients and treating physicians, and support pharmaceutical companies to focus their drug development efforts on the right molecules in the right indications. We enable research through the image-based quantification of single-cell phenotypes - all performed directly in primary patient material with minimal amounts of manipulation and requiring minimal amounts of sample. We integrate these data using cutting edge methods of statistics and machine learning to generate actionable insights for our customers. Our mission is to help you make the best possible biomedical decisions.

Total Funding Amount:

$6M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Vienna, Wien, Austria

Founded Date:

2017-01-01

Contact Email:

office(AT)allcyte.com

Founders:

Berend Snijder, Giulio Superti-Furga, Gregory Vladimer, Nikolaus Krall

Number of Employees:

11-50

Last Funding Date:

2020-07-09

IPO Status:

Private

Industries:

© 2025 bioDAO.ai